title: Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia.
abstract: Tumor necrosis factor (TNF) and interleukin (IL)-1 are two cytokines for which naturally occurring inhibitors have been identified. The present study was undertaken to evaluate the extent to which scavenging of TNF in bacteremia attenuates the plasma levels of IL-1 receptor antagonist (IL-1ra) and soluble TNF receptors (sTNFR). Ten male baboons received 2 x 10(9) colony-forming units/kg live Escherichia coli over 2 h and were subjected to either placebo or anti-TNF antibody (anti-TNF Ab) treatment (1 mg/kg CDP571, Celltech, UK) 2 h before E. coli infusion (observation time: 72h). IL-1ra (range: 50-100 ng/ml) and sTNFR (range: 55kDa, 20-25 ng/ml; 75 kDa, 30-35 ng/ml) release was more sustained than that of IL-1 and TNF and was significantly attenuated by anti-TNF treatment, as were the circulating levels of IL-1, IL-8, and monocyte chemotactic peptide-1 (MCP-1) in the anti-TNF Ab group. We conclude that the increase in circulating natural cytokine modulators observed in nonhuman primate bacteremia is under the partial control of endogenous TNF because it was influenced by anti-TNF pretreatment. This attenuation is comparable to the anti-TNF effect on the chemokine MCP-1.
authors.affiliation: Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Redl
authors.forename: G
authors.initials: G
authors.lastname: Schlag
authors.forename: E
authors.initials: E
authors.lastname: Paul
authors.forename: S
authors.initials: S
authors.lastname: Bahrami
authors.forename: W A
authors.initials: WA
authors.lastname: Buurman
authors.forename: R M
authors.initials: RM
authors.lastname: Strieter
authors.forename: S L
authors.initials: SL
authors.lastname: Kunkel
authors.forename: J
authors.initials: J
authors.lastname: Davies
authors.forename: R
authors.initials: R
authors.lastname: Foulkes
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D016470:Bacteremia / Q000097:blood / Q000503:physiopathology*; D018932:Chemokine CCL2 / Q000097:blood; D004927:Escherichia coli Infections; D007375:Interleukin-1 / Q000097:blood*; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D010215:Papio; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood; D012995:Solubility; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism* / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; D018932:Chemokine CCL2; D007375:Interleukin-1; D016209:Interleukin-8; D017472:Receptors, Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha